BMRN | tickerfilter.com

Fundamental analysis

26%

Profitability 20%

Dept financing 9%

Liquidity 69%

Performance 27%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.16%

1 Month

5.74%

3 Months

13.16%

6 Months

4.60%

1 Year

-15.11%

2 Year

-29.75%

Key data

Stock price

$60.43

P/E Ratio

32.72

DAY RANGE

$58.50 - $61.19

EPS

$1.82

52 WEEK RANGE

$50.76 - $73.51

52 WEEK CHANGE

-$15.14

MARKET CAP

11.417 B

YIELD

N/A

SHARES OUTSTANDING

192.323 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-04-2025

BETA

-0.01

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,478,248

AVERAGE 30 VOLUME

$2,388,085

Company detail

CEO: Jean-Jacques Bienaimé
Region: US
Website: biomarin.com
Employees: 3,080
IPO year: 1999

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

BMRN - BIOMARIN PHARMACEUTICAL INC